A charity-industry collaboration in the UK has launched an initiative to find new epigenetic drug treatments to improve the lives of people affected by respiratory diseases.
The respiratory collaboration brings together three charities, namely Asthma UK, the British Lung Foundation and MRC Technology – an independent life science medical research body – with Anglo-Swedish pharma major AstraZeneca (LSE: AZN).
Together they will investigate the link between epigenetics, changes in the expression of genes which could be attributed to lifestyle and other external factors affecting the body, and respiratory disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze